MLH1 and neoplasm: Immunhistochemistry data (Table 1) demonstrated a significant reduction of SPTAN1 in all MLH1 deficient tumor sections, while SPTAN1 could be clearly detected in all MLH1 proficient CRC tissues; exemplary results are shown in Figure 4B and D, respectively.